ErikPSulmanMD

Physician

Dr. Sulman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
560 1st Ave
Fl 2
New York, NY 10016
Phone+1 646-501-8900

Fax+1 646-501-8904

University of Texas M D Anderson Cancer CenterResidency, Radiation Oncology, 2004 - 2008
Albert Einstein Medical CenterInternship, Transitional Year, 2003 - 2004
Lewis Katz School of Medicine at Temple UniversityClass of 2003

PubMed

Targeted radionuclide therapy for gliomas: Emerging clinical trial landscape.
Michael Weller, Nathalie L Albert, Norbert Galldiks, Andrea Bink, Matthias Preusser
Neuro-Oncology. 2024-12-09
1 citations
Radioligand therapies in meningioma: Evidence and future directions.
Maximilian J Mair, Emeline Tabouret, Derek R Johnson, Erik P Sulman, Patrick Y Wen
Neuro-Oncology. 2024-12-09
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.
Jann N Sarkaria, Karla V Ballman, Sani H Kizilbash, Erik P Sulman, Caterina Giannini
JAMA Oncology. 2024-12-01

Journal Articles

BCAT1 and miR-2504: Novel Methylome Signature Distinguishes spindle/desmoplastic Melanoma from Superficial Malignant Peripheral Nerve Sheath Tumor
Erik P Sulman, Matija Snuderl, George Jour, Phyu P Aung, Nature
A Co-Clinical Radiogenomic Validation Study - Conserved Magnetic Resonance Radiomic Appearance of Periostin Expressing Glioblastoma in Patients and Xenograft Models
Sanjay K Singh, Ashok J Kumar, Rivka R Colen, Gregory N Fuller, Frederick F Lang, Erik P Sulman, Clinical Cancer Research
Cell Surface Notch Ligand DLL3 Is a Therapeutic Target in Isocitrate Dehydrogenase Mutant Glioma
John G Golfinos, Daniel P Cahill, Erik P Sulman, David Zagzag, Clinical Cancer Research

Lectures

Predictive Molecular Biomarkers: Enriching Clinical Trial Populations for Glioblastoma
2013 Annual Meeting, Chicago, Illinois, USA
Predictive Molecular Biomarkers: Enriching Clinical Trial Populations for Glioblastoma
American Society of Clinical Oncology, 2013 Annual Meeting, Chicago, Illinois, USA

Novocure Announces Strategic Alliance with NYU Grossman School of Medicine for Preclinical and Clinical ResearchOctober 29th, 2020
NYU Langone Health Launches New Molecular Assay to Identify Patients with Brain TumorsOctober 24th, 2019
How a Brain Tumor Taught Me to Embrace MyselfDecember 6th, 2017
Join now to see all